Results 111 to 120 of about 6,602 (127)

Balancing Promise and Peril: Hemophilia Gene Therapy Insights. [PDF]

IUBMB Life
Akula S, Borroni E, Cottonaro A, Follenzi A, Merlin S.   +4 more
europepmc   +1 more source

Screening of Single-Domain Antibodies to Adeno-Associated Viruses with Cross-Serotype Specificity and a Wide pH Tolerance. [PDF]

Viruses
Guo H, Wang S, Feng L, Xu W, Zhang J, Zhou X, Ma N.   +6 more
europepmc   +1 more source

Modeling Obesity and Weight Loss in Mice Using Novel AAV Approaches. [PDF]

Obesity (Silver Spring)
Sellers HG, Brown ZL, Khalil NS, Haigh SB, Shivers MA, Patel TV, Joshua AT, Weintraub NL, Barman SA, Belin de Chantemele EJ, Kirov SA, Stepp DW, Fulton DJR.   +12 more
europepmc   +1 more source

AAV vectors for long-term gene therapy of hemophilia B: Are we there yet? [PDF]

Mol Ther
Srivastava A.
europepmc   +1 more source

Functional In Vitro Assessment of rAAV-Delivered Retinol Dehydrogenase 12 (RDH12) Activity. [PDF]

Int J Mol Sci
Pavlova P, Averina M, Gurtsieva D, Galieva A, Ivanov RA, Karabelsky A, Minskaia E.   +6 more
europepmc   +1 more source

Protocol for adeno-associated virus-mediated gene delivery to accelerate pancreatic carcinogenesis in mice. [PDF]

STAR Protoc
Li H, Shi Z, Shen S, Kong B.
europepmc   +1 more source

Emerg Infect Dis [PDF]

core   +3 more sources

Mouse Alport podocytes are susceptible to AAV9 transduction in vivo. [PDF]

Kidney Int
Lin MH, Omachi K, Begin JF, Richardson JL, Miner JH.   +4 more
europepmc   +1 more source

Safety and vision outcomes of subretinal gene supplementation therapy in <i>PDE6A</i>-associated retinitis pigmentosa: a non-randomised controlled trial. [PDF]

Br J Ophthalmol
Reichel FF, Fischer MD, Stingl K, Kuehlewein L, Seitz I, Peters T, Ziegler M, Wilhelm B, Kohl S, Weisschuh N, Martus P, Seeliger M, Muehlfriedel R, Paquet-Durand F, Tsang SH, Bartz-Schmidt KU, Ueffing M, Zrenner E, Biel M, Wissinger B, Michalakis S, RD-Cure Consortium.   +21 more
europepmc   +1 more source